• Explore /
  • Poster
  • / MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.

MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.

Abstract Poster

Authors

null

Gulam Abbas Manji

Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY

Gulam Abbas Manji , Brian William Labadie , Shing M Lee , Ilenia Pellicciotta , Liner Ge , Sarah Sta Ana , Naomi Sender , Isabelle Ross , Winston Wong , Alexander G Raufi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies

Sub Track

Immunotherapies

Clinical Trial Registration Number

NCT04214418

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 45)

DOI

10.1200/GO.2023.9.Supplement_1.45

Abstract #

45

Poster Bd #

C2

Abstract Disclosures

Similar Posters

First Author: Alexander Raufi

First Author: Lisa Zimmer

First Author: Nagla Fawzy Abdel Karim

First Author: Dana Backlund Cardin